Yüklüyor......
The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera.
One year in the coronavirus disease 2019 (COVID-19) pandemic, the first vaccines are being rolled out under emergency use authorizations. It is of great concern that newly emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can escape antibody-mediated protection induce...
Kaydedildi:
| Yayımlandı: | medRxiv |
|---|---|
| Asıl Yazarlar: | , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Cold Spring Harbor Laboratory
2021
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7852247/ https://ncbi.nlm.nih.gov/pubmed/33532796 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/2021.01.26.21250543 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|